LAB

0.60191.92%
ED

Eli Decatur Casdin

Independent Non-Employee Director

Mr. Eli Decatur Casdin, M.B.A, is Director of GeneDx, Inc. since July 2020. Mr. Casdin serves as Board Observer of Verana Health, Inc. He has been an Independent Non-Employee Director of Standard BioTools Inc. since April 05, 2022 and PrivaPath Diagnostics Limited since June 07, 2021. He served as Independent Director at 2seventy bio, Inc. since March 20, 2024 until May 13, 2025. He serves as Director of IDRx, Inc. He served as Independent Director at SomaLogic, Inc. since December 22, 2020. He serves as Director at Prominex, Inc. Mr. Casdin serves as a Director at GeneDx Holdings Corp. (formerly known as Sema4 Holdings Corp.) (formerly known as Mount Sinai Genomics, Inc.) since July 2021 and served as its Chief Executive Officer since July 2020 until July 2021. He served as Chief Executive Officer of EQRx, Inc. (Former Name: CM Life Sciences III Inc.) since January 2021. He served as a Director at Genome Medical Holding Co (formerly known as Genome Medical, Inc.) since November 2021 and DNA Script SAS since July 2020. He serves as Director of PAIGE. AI, Inc. He was Director at Absci, CORP (formerly known as AbSci, LLC) since October 2020 to July 11, 2022. He is a Director of Vineti, Inc. since October 2020. He is Supervisory Board Member at Leyden Laboratories B. V. He served as Board Observer at Verve Therapeutics, Inc. since September 2020 until September 2021. He has been Chief Executive Officer at CM Life Sciences, Inc. since July 2020 and serves as its Director since July 2020. He served as an Independent Director at Century Therapeutics, Inc. from February 2021 to October 1, 2022 and also serves as a Director at Thrive Earlier Detection Corp. He serves as the Chief Executive Officer, Founder, Chief Investment Officer & Managing Partner at Casdin Capital, LLC. He is Founder, Chief Investment Officer & Managing Partner since 2011 at Casdin Capital, LLC. He has joined the Casdin Capital in 2011. He serves as Director at Cedilla Therapeutics, Inc. since October 25, 2021. He serves on the Board of Thrive Earlier Detection Corp. He is a Board Advisor of Ventus Therapeutics U. S. Inc. He had been an Independent Director of Tenaya Therapeutics, Inc. since August 2019 until December 2022. Mr. Casdin served as Investment Professional at AllianceBernstein LP. He joined AllianceBernstein LP in 2007 and served as an Analyst in a thematic investment group until 2011. Mr. Casdin served as an Equity Analyst at Bear Stearns Companies Inc. Research Division. He was employed at Bear Stearns as an Associate in 2007. Mr. Casdin served as a Research Analyst at Bear Stearns and Cooper Hill Partners, specializing in healthcare investments in life sciences tools, diagnostics and medical devices. Mr. Casdin was employed at Cooper Hill Partners, L. L.C as an Analyst from 2003 to 2006. He served as a Founder at EDMC from 1994 to 2011. He serves as a Director of C2i Genomics, Inc, GeneMatters, LLC, Genomatica, Inc. New York Genome Center, Prominex Inc. Sexton Biotechnologies and Verana Health, Inc. He served as a Director of Exact Sciences Corporation since October 2017 until September 21, 2020. Mr. Casdin is a Board Observer of Invitae since 2013. He also serves as a Director at Einstein Medical, Maze Therapeutics, Mnemo Therapeutics, PACT Pharma, Inc. and Tango Therapeutics. Mr. Casdin helped make a name for himself by writing a 108-page report titled The Dawn of Molecular Medicine. Prior to founding Casdin, he served as a Vice President at Alliance Bernstein from 2007 to 2011, where he was a Member of the Thematic investment research group researching investment implications of new technologies for the life science and healthcare sectors. During his tenure at Alliance he authored the Alliance Bernstein black book, The Dawn of Molecular Medicine. Previously, he was a Research Analyst at Bear Sterns and before that, Cooper Hill Partners where he analyzed healthcare investments in life science tools, diagnostics and medical devices. He had been Independent Director of EQRx, Inc. since January 2021 until November 2022. He serves as a director or an observer on various boards for a number of public and private life sciences companies, trade groups and academic institutes including Rockefeller University and The Columbia University School of General Studies Board of Visitors. He serves as Board Observer at Insitro, Inc. He has analyzing and investing in disruptive technologies and business models in Life Sciences and Healthcare. He also studied at University of Vermont. He previously served as the Chief Executive Officer of CMLS from July 2020 to July 2021. He completed his M. B.A. from Columbia Business School in Finance and Accounting in 2003. Mr. Casdin completed Bachelor of Science from Columbia University School of General Studies in 2003.

Positions